ADONIS 00071 04891 00061G

British Iournal o/Haematologu. 1991, 77, 375-381

Reduction of platelet glycoprotein Ib in uraemia E. M. SLOAND. J. A. SLOAND,* K . P R O D O L J 2 . t H.G. K L E I N , M. w. Y U , t L. H A R V A T H t A N D Department of Transfusion Medicine, National lnstitutes of Health, Bethesda, Maryland 20892, 'University of Rochester School of Medicine and Dentistry, Rochester, New York 14620, and tCenter for Biologics Evaluation and Research, FDA, Bethesda, Maryland 20892, U.S.A.

w. F R I C K E t

Received 12 June 1 9 9 0 ; accepted for publication 31 October 1 9 9 0

Summary. Patients with uraemia have abnormal platelet function that may be partially corrected by haemodialysis, cryoprecipitate or 1-desamino-8-karginine vasopressin (DDAVP). We studied the platelet von Willebrand factor receptor. glycoprotein Ib (GPIb).and plasma von Willebrand factor (vWF)in uraemic patients undergoing chronic haemodialysis. Using the slope of agglutination of formalin-fixed platelets as an index of response to ristocetin (with a constant amount of normal plasma as a source of vWF), we found the response of platelets from uraemic patients, both before (2.7f1.5. n=40)andafterdialysis(1.2f1.2, n=40) tobe significantly less than that for normal controls (14.1f 10.2. n = 20: P < 0.001 ). In addition, the agglutination response of platelets obtained after dialysis was less than that of platelets obtained before dialysis (P

Reduction of platelet glycoprotein Ib in uraemia.

Patients with uraemia have abnormal platelet function that may be partially corrected by haemodialysis, cryoprecipitate or 1-desamino-8-D-arginine vas...
1MB Sizes 0 Downloads 0 Views